Business Context and Reporting Period
This Form 8-K filing by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) reports on the 2018 Annual Meeting of Stockholders held on June 27, 2018. The report was filed on June 28, 2018. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The primary event reported is the outcome of the 2018 Annual Meeting. Of the 30,192,373 shares outstanding, 26,305,917 shares (87.1%) were present or represented by proxy. Key outcomes include:
- Election of Directors: All eight nominees were re-elected. Broker non-votes totaled 9,294,107 shares for each director.
- Ratification of Auditors: Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
| Proposal | For | Against/Withheld | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (Aggregate) | Varies by nominee | Varies by nominee | N/A | 9,294,107 |
| Ratification of KPMG LLP | 25,515,605 | 771,122 | 19,190 | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural results of the shareholder vote.
Important Facts for Investors to Verify
- Verify the company name discrepancy: The input metadata listed "Viridian Therapeutics, Inc.," but the filing is for "Miragen Therapeutics, Inc."
- Confirm the high level of broker non-votes (9,294,107 shares) regarding the election of directors, which indicates a significant portion of shares held in street name did not receive voting instructions.
- Review the specific vote counts for individual directors, as "Withheld" votes ranged from approximately 52,000 to 1.34 million shares.
- Check subsequent filings for financial data, as this 8-K contains no financial performance metrics.